Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of ...
Gilead will lay off 108 workers from Arcellx’s site at 800 Bridge Parkway in Redwood City, CA, according to a Worker ...
Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...
A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to ...
Olympus has inked a collaboration deal for the global distribut | Olympus inked a collaboration deal for the global ...
Roche’s Foundation Medicine has linked with Fulgent Genetics to offer a new diagnostic test that identifies a person’s ...
The American Biotech Innovation Alliance launches to unify domestic strategy amid global competition
A cross-section of biotech leaders is launching the American Biotech Innovation Alliance (ABIA) with the goal of uniting ...
After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals ...
After some tough feedback from the FDA on the path forward for its lead gene therapy, Passage Bio has launched a strategic ...
UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio ...
Windward Bio is in full sail with a $165 million crossover financing to push its long-acting anti-TSLP antibody into phase 3, ...
Funding for privately traded Swiss biotechs hit a new high last year, climbing 38% to 1.15 billion Swiss francs ($1.5 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results